Our Mission
Spero Therapeutics is dedicated to delivering differentiated medicines to help patients suffering from rare diseases and multidrug-resistant (MDR) bacterial infections.
Tebipenem HBr
An investigational oral carbapenem being developed for the treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis (AP)
Tebipenem HBr (tebipenem pivoxil hydrobromide) is an investigational oral carbapenem being developed for the treatment of cUTI and AP to potentially help patients avoid hospitalizations and/or reduce the duration of in-patient therapy. If approved, Tebipenem is positioned to be the first oral carbapenem for this condition.
Partnerships
Spero Therapeutics believes that forming collaborations with external partners is essential to maximizing the reach and impact of our innovative therapies for patients.
Investor Relations
Stock information, SEC filings, corporate governance, IR resources and more.
Careers
Join our life-changing mission to deliver differentiated treatments for those affected by rare and MDR bacterial infections. We seek individuals with unique talents who share our passion.